Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients

@article{Sjstrm1998RandomisedPT,
  title={Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients},
  author={Lars Sj{\"o}str{\"o}m and Aila Rissanen and Teis Andersen and Mark Boldrin and Michel Krempf},
  journal={The Lancet},
  year={1998},
  volume={352},
  pages={167-172}
}
BACKGROUND We undertook a randomised controlled trial to assess the efficacy and tolerance of orlistat, a gastrointestinal lipase inhibitor, in promoting weight loss and preventing weight regain in obese patients over a 2-year period. METHODS 743 patients (body-mass index 28-47 kg/m2), recruited at 15 European centres, entered a 4-week, single-blind, placebo lead-in period on a slightly hypocaloric diet (600 kcal/day deficit). 688 patients who completed the lead-in were assigned double-blind… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 262 CITATIONS

Results of obesity treatment.

  • Annales d'endocrinologie
  • 2002
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Benefits and risks of antiobesity agents

VIEW 8 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

1997
2019

CITATION STATISTICS

  • 22 Highly Influenced Citations

  • Averaged 12 Citations per year over the last 3 years

Similar Papers

Loading similar papers…